A Phase 1 interventional study of DAY301 in Advanced or Metastatic Solid Tumors, sponsored by Day One Biopharmaceuticals, Inc.. Recruiting at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.
Sponsored by Day One Biopharmaceuticals, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and anti-tumor activity of DAY301, a PTK7-directed antibody-drug conjugate (ADC) in participants with advanced or metastatic solid tumors. The study comprises of 2 phases: Phase 1a dose escalation where participants will be administered DAY301 at escalating dose levels to assess safety and tolerability, and to determine the maximum tolerated dose (MTD) and/or the recommended dose (RD); In Phase 1b dose expansion, DAY301 will be evaluated in dose expansion cohorts.
Day One Biopharmaceuticals, Inc. is the lead sponsor of 8 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
(Participants must have been previously treated with standard of care systemic therapy, have refused standard therapy, or have no standard therapy available).
Exclusion Criteria:
Phase 1b disease-specific exclusion criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DAY301 will be administered at different dose levels in dose escalation and at the RD in dose expansion cohorts.
Drug: DAY301
DAY301 will be administered as IV infusion
Phase 1a: Dose Escalation: Number of participants with reported Dose Limiting Toxicities (DLTs)
To evaluate adverse events (AEs) considered dose limiting toxicities that occur in the first cycle of treatment (within a DLT observation period).
Time frame: Within 21 days of first infusion (Day 1)
Phase 1a: Dose Escalation: Number of participants with reported adverse events (AEs) and serious AEs (SAEs)
The type, incidence, and severity of AEs and SAEs will be determined using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
Time frame: through the duration of treatment, up to approximately 12 months
Phase 1a: Dose Escalation: Frequency of dose interruptions
The frequency at which dose interruptions occur during dose-escalation
Time frame: through the duration of treatment, up to approximately 12 months
Phase 1a: Dose Escalation: Duration of dose interruptions
The duration of dose interruptions that occur during dose-escalation.
Time frame: through the duration of treatment, up to approximately 12 months
Phase 1a: Dose Escalation: Frequency of dose reductions
The frequency at which dose reductions occur during dose-escalation.
Time frame: through the duration of treatment, up to approximately 12 months
Phase 1a: Dose Escalation: Duration of dose reductions
The duration of dose reductions that occur during dose-escalation.
Time frame: through the duration of treatment, up to approximately 12 months
Phase 1b: Dose Expansion: Objective response rate
Objective response rate based on best overall response (BOR) will be assessed by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
Time frame: through the duration of treatment, up to approximately 12 months
Phase 1b: Dose Expansion: Number of participants reporting AEs and SAEs
The type, incidence, and severity of AEs and SAEs will be determined using the NCI CTCAE v5.0.
Time frame: through the duration of treatment, up to approximately 12 months
Phase 1b: Dose Expansion: Frequency of dose interruptions
The frequency at which dose interruptions occur during dose-expansion.
Time frame: through the duration of treatment, up to approximately 12 months
Phase 1b: Dose Expansion: Duration of dose interruption
The duration of dose interruptions that occur during dose-expansion.
Time frame: through the duration of treatment, up to approximately 12 months
Phase 1b: Dose Expansion: Frequency of dose reductions
The frequency at which dose reductions occur during dose-expansion.
Time frame: through the duration of treatment, up to approximately 12 months
Phase 1b: Dose Expansion: Duration of dose reductions
The duration of dose reductions that occur during dose-expansion.
Time frame: through the duration of treatment, up to approximately 12 months
Phase 1a and Phase 1b: Maximum concentration (Cmax) of DAY301
Blood samples will be collected at indicated time points for the analysis of pharmacokinetic parameters.
Time frame: Varying timepoints through the duration of treatment, up to approximately 12 months
Phase 1a and Phase 1b: time to Cmax (Tmax) of DAY301
Blood samples will be collected at indicated time points for the analysis of pharmacokinetic parameters.
Time frame: Varying timepoints through the duration of treatment, up to approximately 12 months
Phase 1a and Phase 1b: area under the curve (AUC) of DAY301
Blood samples will be collected at indicated time points for the analysis of pharmacokinetic parameters.
Time frame: Varying timepoints through the duration of treatment, up to approximately 12 months
Phase 1a and Phase 1b: terminal half-life (t1/2) of DAY301
Blood samples will be collected at indicated time points for the analysis of pharmacokinetic parameters.
Time frame: Varying timepoints through the duration of treatment, up to approximately 12 months
Phase 1a Dose Escalation: Objective response rate
Objective response rate based on BOR will be assessed by investigators according to RECIST v1.1.
Time frame: through the duration of treatment, up to approximately 12 months
Phase 1a and 1b: Clinical Benefit rate (CBR)
Clinical Benefit rate will be assessed by investigators according to RECIST v1.1.
Time frame: through the duration of treatment, up to approximately 12 months
Phase 1a and 1b: duration of response (DOR)
Duration of response will be assessed by investigators according to RECIST v1.1.
Time frame: through the duration of treatment, up to approximately 12 months
Phase 1a and 1b: time to response (TTR)
Time to response will be assessed by investigators according to RECIST v1.1.
Time frame: through the duration of treatment, up to approximately 12 months
Phase 1a and 1b: Progression-free survival
Progression-free survival will be assessed by investigators according to RECIST v1.1.
Time frame: through the duration of treatment, up to approximately 12 months
Phase 1b: Overall survival
Overall survival will be assessed by investigators.
Time frame: through the duration of treatment, up to approximately 12 months
Phase 1a and 1b: Number of participants with positive antidrug antibodies (ADAs)
Assessed by the measure of anti-drug antibodies in serum.
Time frame: varying timepoints through the duration of treatment, up to approximately 12 months
Started Nov 2024 (actual). Primary completion is estimated for Dec 2027, 37 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Day One Biopharmaceuticals, Inc.